First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)-Reference-Cited by-同舟云学术

First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)

Published:2022-06-21 Issue:1 Volume:72 Page:91-99
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Descourt Renaud,Greillier Laurent,Perol Maurice,Ricordel Charles,Auliac Jean-Bernard,Falchero Lionel,Gervais Radj,Veillon Rémi,Vieillot Sabine,Guisier Florian,Marcq Marie,Justeau Grégoire,Bigay-Game Laurence,Bernardi Marie,Fournel Pierre,Doubre Hélène,Pinsolle Julian,Amrane Karim,Chouaïd Christos^ORCID,Decroisette Chantal

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-022-03232-2.pdf

Reference22 articles.

1. Institut National du Cancer (2016) Accès aux tests moléculaires EGFR, RAS et BRAF. Résultats d’une enquête dans 5 régions françaises

2. Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833. https://doi.org/10.1056/NEJMoa1606774

3. Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028. https://doi.org/10.1056/NEJMoa1501824

4. Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL (2016) Pembrolizumab (Keytruda). Hum Vaccin Immunother 12:2777–2789. https://doi.org/10.1080/21645515.2016.1199310

5. Chatterjee M, Turner DC, Felip E et al (2016) Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol 27:1291–1298. https://doi.org/10.1093/annonc/mdw174

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brain Metastases as Inaugural Sign of Non-Small Cell Lung Carcinoma: Case Series and Review of Literature;Cancers;2024-09-08

2. Interdisziplinäre Behandlungsstrategien bei Hirnmetastasen*;InFo Hämatologie + Onkologie;2024-05

3. Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan;Frontiers in Oncology;2024-04-30

4. Interdisziplinäre Behandlungsstrategien bei Hirnmetastasierung;InFo Neurologie + Psychiatrie;2024-02

5. Three-Year Overall Survival of Patients With Advanced Non–Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study);Journal of Immunotherapy;2023-10-09